CA2430495A1 - Virus oncolytique - Google Patents
Virus oncolytique Download PDFInfo
- Publication number
- CA2430495A1 CA2430495A1 CA002430495A CA2430495A CA2430495A1 CA 2430495 A1 CA2430495 A1 CA 2430495A1 CA 002430495 A CA002430495 A CA 002430495A CA 2430495 A CA2430495 A CA 2430495A CA 2430495 A1 CA2430495 A1 CA 2430495A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- reovirus
- protein
- amino acid
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 244000309459 oncolytic virus Species 0.000 title description 2
- 241000700605 Viruses Species 0.000 claims abstract description 119
- 241000702263 Reovirus sp. Species 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 230000003612 virological effect Effects 0.000 claims abstract description 12
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 11
- 230000035899 viability Effects 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 241001493065 dsRNA viruses Species 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 101150109178 M1 gene Proteins 0.000 claims description 13
- 241000712464 Orthomyxoviridae Species 0.000 claims description 9
- 241000711504 Paramyxoviridae Species 0.000 claims description 9
- 241000711931 Rhabdoviridae Species 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 241000702247 Reoviridae Species 0.000 claims description 7
- 108700018523 Reovirus mu2 Proteins 0.000 claims description 7
- 101150080963 S4 gene Proteins 0.000 claims description 7
- 101150084684 L3 gene Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 101150075200 S-2 gene Proteins 0.000 claims description 3
- 241000004176 Alphacoronavirus Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 241000701372 Iridovirus Species 0.000 claims description 2
- 101150075239 L1 gene Proteins 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241001068263 Replication competent viruses Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 28
- 210000004072 lung Anatomy 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000012010 growth Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 241000702244 Orthoreovirus Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000000174 oncolytic effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 2
- 241000023308 Acca Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101150027802 L2 gene Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 208000008104 Reoviridae Infections Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- -1 5-bromo-4-chloro-3-indolyl Chemical group 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241001274197 Scatophagus argus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des méthodes de réduction de la viabilité d'une cellule tumorale, par l'infection par un virus d'un néoplasme chez un mammifère ou par le traitement d'un néoplasme chez un mammifère, au moyen de certains virus non naturels. Des réassortiments viraux, comme, par exemple des réassortiments réoviraux, et des techniques d'identification des virus sensibles à PKR sont également décrits.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25013100P | 2000-12-01 | 2000-12-01 | |
| US60/250,131 | 2000-12-01 | ||
| US32701601P | 2001-10-05 | 2001-10-05 | |
| US60/327,016 | 2001-10-05 | ||
| PCT/CA2001/001703 WO2002043647A2 (fr) | 2000-12-01 | 2001-11-30 | Virus oncolytique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2430495A1 true CA2430495A1 (fr) | 2002-06-06 |
Family
ID=26940619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002430495A Abandoned CA2430495A1 (fr) | 2000-12-01 | 2001-11-30 | Virus oncolytique |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1339736A2 (fr) |
| JP (1) | JP2004519431A (fr) |
| AU (2) | AU2002220416A1 (fr) |
| CA (1) | CA2430495A1 (fr) |
| WO (2) | WO2002043647A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111200A1 (fr) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Souches de reovirus et procedes d'utilisation de celles-ci |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP1917351A4 (fr) | 2005-08-01 | 2009-12-16 | Univ Technologies Int | Réovirus atténué |
| CA2678721C (fr) * | 2007-03-12 | 2018-02-13 | Oncolytics Biotech Inc. | Reovirus ayant des sequences modifiees |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2019237063A1 (fr) * | 2018-06-07 | 2019-12-12 | Emory University | Réovirus modifiés, particules et utilisations dans le traitement de troubles prolifératifs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| CA2323067A1 (fr) * | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite |
-
2001
- 2001-11-30 EP EP01998300A patent/EP1339736A2/fr not_active Ceased
- 2001-11-30 JP JP2002545626A patent/JP2004519431A/ja active Pending
- 2001-11-30 AU AU2002220416A patent/AU2002220416A1/en not_active Abandoned
- 2001-11-30 WO PCT/CA2001/001703 patent/WO2002043647A2/fr not_active Application Discontinuation
- 2001-11-30 CA CA002430495A patent/CA2430495A1/fr not_active Abandoned
- 2001-12-03 AU AU2002243257A patent/AU2002243257A1/en not_active Abandoned
- 2001-12-03 WO PCT/US2001/045108 patent/WO2002050304A2/fr not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111200A1 (fr) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Souches de reovirus et procedes d'utilisation de celles-ci |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002243257A1 (en) | 2002-07-01 |
| EP1339736A2 (fr) | 2003-09-03 |
| WO2002050304A3 (fr) | 2002-11-28 |
| WO2002043647A3 (fr) | 2003-01-03 |
| AU2002220416A1 (en) | 2002-06-11 |
| JP2004519431A (ja) | 2004-07-02 |
| WO2002043647A2 (fr) | 2002-06-06 |
| WO2002050304A2 (fr) | 2002-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clarke et al. | Reovirus-induced apoptosis: a minireview | |
| Cowley et al. | Genetic reassortants for identification of the genome segment coding for the bluetongue virus hemagglutinin | |
| Yun et al. | Isolation and genomic characterization of a classical Muscovy duck reovirus isolated in Zhejiang, China | |
| Sherry et al. | The reovirus M1 gene, encoding a viral core protein, is associated with the myocarditic phenotype of a reovirus variant | |
| US20040115170A1 (en) | Oncolytic virus | |
| Parvin et al. | Comparison of pathogenicity of subtype H9 avian influenza wild-type viruses from a wide geographic origin expressing mono-, di-, or tri-basic hemagglutinin cleavage sites | |
| CA2430495A1 (fr) | Virus oncolytique | |
| Blackhall et al. | Serine protein kinase activity associated with rotavirus phosphoprotein NSP5 | |
| Li et al. | Characterization and pathogenicity of a novel mammalian orthoreovirus from wild short-nosed fruit bats | |
| Van de Zande et al. | Central nervous system signs in chickens caused by a new avian reovirus strain: a pathogenesis study | |
| Sandekian et al. | A single amino acid substitution in the mRNA capping enzyme λ2 of a mammalian orthoreovirus mutant increases interferon sensitivity | |
| Jiang et al. | Genetic characterization and pathogenicity of a divergent broiler‐origin orthoreovirus causing arthritis in China | |
| Yin et al. | Isolation and characterization of a novel chicken astrovirus in China | |
| KR19990072201A (ko) | 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법 | |
| Lu et al. | Synergistic action of phages and lytic proteins with antibiotics: a combination strategy to target bacteria and biofilms | |
| Middleton et al. | Thermostabilizing mutations in reovirus outer-capsid protein μ1 selected by heat inactivation of infectious subvirion particles | |
| Grande et al. | Optimal conditions for the growth, purification and storage of the avian reovirus S1133 | |
| Ramig et al. | Genetics of reoviruses | |
| Fields | Genetics of reovirus | |
| Jabre et al. | Amino acid substitutions in σ1 and μ1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells | |
| Yawei et al. | Subgenomic S1 segments are packaged by avian reovirus defective interfering particles having an S1 segment deletion | |
| Ren et al. | Isolation and pathogenicity analysis of mink orthoreoviruses | |
| ES2241506T3 (es) | Uso de ribozimas en la detección de agentes adventicios. | |
| Jiang et al. | Genetic characterization of a new mammalian reovirus, type 2 Winnipeg (T2W) | |
| Schwartz et al. | Differential induction of apoptosis in demyelinating and nondemyelinating infection by mouse hepatitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |